Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by ...

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51. The drug – formerly known as SRP-5051 – is ...

Ayvakit has been recommended by NICE for ASM – an umbrella term that covers aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse partnerships lighting up the industry—like Biogen & Neomorph, Inc.’s groundbreaking ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

Boston, US-based XRHealth is leading the deal, acquiring NeuroReality of the Netherlands for an undisclosed sum, combining their products and expertise in the use of XR and virtual reality software ...